公开(公告)号：US11492409B2

公开(公告)日：2022-11-08

申请号：US16426914

申请日：2019-05-30

Applicant: NOVARTIS AG

Inventor： Aida Abujoub ,  John Blankenship ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Haihui Lu

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C07K14/715 ,  C07K14/725 ,  C07K14/735 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

公开(公告)号：US20190382500A1

公开(公告)日：2019-12-19

申请号：US16439495

申请日：2019-06-12

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783 ,  A61P35/00 ,  A61K35/17

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.